EVE Health Begins Real-World Prescriptions for Dyspro, Targets Major Women's Health Market

EVE Health Group (ASX: EVE) has marked a key commercial milestone with its flagship cannabinoid-based therapy Dyspro now prescribed to patients for the first time. The development signals the transition from manufacturing and distribution to active clinical use in Australia, under the Therapeutic Goods Administration's Special Access Scheme and Authorised Prescriber pathways.

Dyspro is a fast-acting pastille designed to relieve dysmenorrhoea and endometriosis symptoms — conditions that affect a significant majority of Australian women during their reproductive years. With more than 70 percent of women affected by menstrual pain and up to 14 percent living with endometriosis, the addressable market is both large and underserved.

Chairman Rod Hannington described the first prescriptions as a validation of EVE’s strategy to combine science-led formulation with accessible patient support.

“This is a major step in our mission to deliver real relief to women with painful menstrual symptoms,” Hannington said. “We are proud to support this launch not only with our product but also with education and community resources through our Reclaim My Cycle initiative.”

The Reclaim My Cycle platform (www.reclaimmycycle.com) was launched alongside Dyspro’s rollout and is designed to bridge the gap between patient awareness, clinical guidance and practical access. The site offers resources for both consumers and practitioners, including plain-language educational materials, prescribing information, and direct access to telehealth services via the TeleDocs Clinic network.

The platform supports EVE’s broader strategy of integrating digital health engagement with clinical adoption. The company has already hosted its first in-clinic educational seminar for healthcare professionals and is developing further practitioner outreach to scale prescribing activity and prepare for potential export opportunities.

Dysmenorrhoea and endometriosis are associated with a considerable economic impact. One study cited by EVE estimates the national cost in Australia at $14.2 billion annually, mostly through lost productivity. EVE believes the effective management of these conditions with targeted therapeutics like Dyspro represents both a health and economic opportunity.

Dyspro’s entry into the market positions EVE Health as a credible player in the women’s health segment and adds commercial momentum to its product pipeline, which also includes Libbo — an orally dissolving cannabinoid film for erectile dysfunction.

The company’s formulation technologies are designed to enhance bioavailability and speed of onset, helping differentiate its products from traditional therapies in large therapeutic categories.

As prescriptions of Dyspro commence and awareness grows through the Reclaim My Cycle platform, EVE is aiming to scale patient access and broaden distribution both domestically and, in time, globally.